Board Meeting Outcome for Approval Of Unaudited Financial Results For The Half Year Ended on 30th September, 2025

Revenue growth above 20%Profit growth above 25%EBITDA margin compressionNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹61.10

prior close

₹62.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+5.3% vs market

Pharmaceuticals peers, median of 157sector-0.2%+5.2% vs sector

On the reaction day the stock moved 5.3 pts more than Nifty Microcap 250 and 5.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.3

10m

+3.5

15m

+3.5

30m

+3.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0-0.3+5.3-0.2+5.2

Next day

+10.2+0.7+9.6+0.5+9.7

+4.7+0.6+4.2+0.6+4.2

-0.5+0.5-1.0+0.5-1.0

-3.1+1.1-4.2+0.4-3.5

-4.4+0.3-4.7-0.6-3.9

+0.7-0.2+0.9-1.1+1.8

15d

+0.2-2.2+2.4-2.1+2.3

+8.0-4.9+12.9-3.2+11.2

+45.3-7.5+52.8-5.9+51.3

+52.1-4.8+56.9-6.4+58.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aptus Pharma reported strong H1 FY26 results. Revenue from operations rose to Rs. 1,437.75 lakhs, up 47.38% from Rs. 975.57 lakhs in H1 FY25. EBITDA grew 36.12% to Rs. 294.55 lakhs, while PAT climbed 33.81% to Rs. 174.69 lakhs. However, both EBITDA margin (20.49%, down 169 bps) and PAT margin (12.15%, down 123 bps) compressed year-on-year due to higher operating costs. The balance sheet strengthened significantly with reserves surging to Rs. 1,484 lakhs from Rs. 193 lakhs and cash rising to Rs. 1,428 lakhs, aided by IPO proceeds of Rs. 1,302 lakhs now fully utilized. Short-term borrowings declined to Rs. 600 lakhs from Rs. 774 lakhs. The auditors (ABKB&Co.) issued a clean limited review report with no qualifications.

Likely market impact

Strong top-line and bottom-line growth signals healthy business momentum, but margin compression may concern investors focused on profitability quality. Improved liquidity and reduced debt are positives for shareholders, though negative operating cash flow (-Rs. 92 lakhs) warrants monitoring.